pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
229
stories
Oct 1, 26
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
Sep 30, 26
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
endpoints
Sep 30, 26
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
Sep 30, 26
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
Sep 30, 26
Opinion: America’s biotech race with China must be won at home
stat
Sep 29, 26
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
Sep 29, 26
STAT+: Overton won’t get a vote before midterms
stat
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
Enanta sheds staffers as key antiviral, immunology readouts loom
fiercebiotech
Sep 29, 26
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
Sep 29, 26
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
stat
Sep 29, 26
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
stat
Sep 28, 26
Risk from toxic metals can persist months after wildfires, Maui study finds
stat
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
Sep 28, 26
STAT+: It really is bleak out there, and list prices matter
stat
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
biospace
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 26, 26
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
endpoints
Sep 25, 26
ADARx raises $446M in biotech’s third largest IPO of 2026, City files to go public
biospace
Sep 25, 26
ADARx scores upsized $446M IPO, while fellow RNA biotech City maps out Nasdaq plans
fiercebiotech
Sep 25, 26
RNAi drug specialist ADARx raises $446M IPO
biopharma dive
Sep 24, 26
Growth mode: 3 biotechs that are staffing up after series B raises
biospace
Sep 23, 26
Pharmas face off for manufacturing talent amidst reshoring efforts
biospace
Sep 22, 26
2026 IPO blitz continues with 4 new biotech filings
biospace
Sep 22, 26
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
biopharma dive
Sep 22, 26
Iambic maintains momentum from string of Big Pharma partnerships by aiming for IPO
fiercebiotech
Sep 21, 26
Iambic signs AbbVie deal, releases next generation of Enchant model
endpoints
Sep 18, 26
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
Sep 18, 26
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
← prev
page 4 of 8
next →